Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S. De Roock W, et al. Among authors: lambrechts d. Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8. Lancet Oncol. 2010. PMID: 20619739
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.
Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, Van Cutsem E. Lambrechts D, et al. Lancet Oncol. 2012 Jul;13(7):724-33. doi: 10.1016/S1470-2045(12)70231-0. Epub 2012 May 17. Lancet Oncol. 2012. PMID: 22608783
Genetic markers of bevacizumab-induced hypertension.
Lambrechts D, Moisse M, Delmar P, Miles DW, Leighl N, Escudier B, Van Cutsem E, Bansal AT, Carmeliet P, Scherer SJ, de Haas S, Pallaud C. Lambrechts D, et al. Angiogenesis. 2014 Jul;17(3):685-94. doi: 10.1007/s10456-014-9424-7. Epub 2014 Feb 21. Angiogenesis. 2014. PMID: 24558090
The Cancer Cell Oxygen Sensor PHD2 Promotes Metastasis via Activation of Cancer-Associated Fibroblasts.
Kuchnio A, Moens S, Bruning U, Kuchnio K, Cruys B, Thienpont B, Broux M, Ungureanu AA, Leite de Oliveira R, Bruyère F, Cuervo H, Manderveld A, Carton A, Hernandez-Fernaud JR, Zanivan S, Bartic C, Foidart JM, Noel A, Vinckier S, Lambrechts D, Dewerchin M, Mazzone M, Carmeliet P. Kuchnio A, et al. Among authors: lambrechts d. Cell Rep. 2015 Aug 11;12(6):992-1005. doi: 10.1016/j.celrep.2015.07.010. Epub 2015 Jul 30. Cell Rep. 2015. PMID: 26235614 Free article.
Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
Lambrechts D, Thienpont B, Thuillier V, Sagaert X, Moisse M, Peuteman G, Pericay C, Folprecht G, Zalcberg J, Zilocchi C, Margherini E, Chiron M, Van Cutsem E. Lambrechts D, et al. Br J Cancer. 2015 Sep 29;113(7):1027-34. doi: 10.1038/bjc.2015.329. Epub 2015 Sep 10. Br J Cancer. 2015. PMID: 26355232 Free PMC article. Clinical Trial.
604 results